Background {#Sec1}
==========

Obstructive sleep apnea (OSA) is a disorder characterized by repeated episodes of upper airway collapse during sleep \[[@CR1]\]. OSA is independently associated with several cardiovascular (CV) diseases including hypertension, myocardial infarction, and stroke \[[@CR2]\]. The effects of OSA during sleep, and especially intermittent hypoxia, may have a predominant role in the vascular consequences of OSA, in association with other mechanisms like oxidative stress, systemic inflammation, impaired glucose and lipid metabolism, endothelial dysfunction and sympathetic activation \[[@CR3]\]. The early detection of individuals at higher risk for CV disease and their treatment is a priority \[[@CR4]\].

The condition of the arterial vessels can be studied by pulse wave velocity (PWV), that can be used as an index of arterial distensibility. Arterial PWV describes how fast a blood pressure (BP) pulse travels from one point to another in an artery. Arterial stiffness is now recognized as a major driver of CV disease, and it depends mainly on age and BP. PWV is a well-established procedure for measuring the arterial stiffness, using arterial tonometry, at the carotid and femoral artery sites: carotid-femoral pulse wave velocity (cf-PWV), the gold standard index. It is a noninvasive biomarker for primary and secondary CV disease prevention, and can be used as an intermediate endpoint for CV events \[[@CR5]\].

OSA is associated with increased arterial stiffness, with an improvement after continuous positive airway treatment (CPAP) \[[@CR6], [@CR7]\].

However, most of OSA patients remain undiagnosed. Daytime sleepiness, a symptom of OSA easily identifiable, was reported in about 20% of all adults with an Apnea-Hypopnea Index (AHI) ≥ 5/h, in population based studies \[[@CR8], [@CR9]\]. Daytime sleepiness does not correlate well with OSA severity parameters and, in its absence, the indication for treatment of OSA is still debatable.

Although non-sleepy patients have an augmented arterial stiffness when compared to non-OSA controls \[[@CR10]\], the very few studies performed did not find a significant improvement after CPAP. Studies that assessed CV risk did not find any benefit either \[[@CR11]\].

The aim of this study is to verify if there are differences in the progression of arterial stiffness in a cohort of patients with OSA, classified as sleepy and non-sleepy, undergoing treatment with CPAP for four months.

Methods {#Sec2}
=======

Study design and patient recruitment {#Sec3}
------------------------------------

This is a prospective cohort study conducted between October 2012 to November 2015. Consecutive patients referred for snoring or OSA-related symptoms to the Sleep Outpatient Clinic of a Pneumology Department were recruited if they were male, younger than 65 years old, and with moderate to severe OSA (AHI \> 15/h) \[[@CR1]\].

The exclusion criteria included other sleep disorders (clinically identified); alcohol abuse; known CV disease beyond hypertension; and other chronic diseases.

Patients with high levels of fasting glucose performed an additional oral glucose tolerance test, and excluded if they were diabetic.

Patients were evaluated monthly for assessment of effectiveness and compliance to therapy, presence of nasal complaints, and changes on the equipment. They were excluded from the study if they were not compliant to CPAP (using at least mean of 4 h/night) \[[@CR12]\], if significant weight loss (\> 5%) occurred, or if there was introduction of new drugs or emergence of new comorbidities.

A laboratorial evaluation, ambulatory blood pressure monitoring (ABPM) and cf-PWV measurements were made before and after 4 months of the beginning of CPAP therapy.

ABPM was performed with Ambulatory Blood Pressure - SpaceLabs model 90207®. Patients were considered hypertensive according ABPM values (current guidelines) or when they were under antihypertensive medication.

At baseline consultation, the Epworth Sleepiness Scale (ESS) was applied and patients were classified as sleepy (ESS \> 10) or non- sleepy (ESS ≤ 10) \[[@CR13]\]. The comorbidities and drug treatments were registered.

A detailed operational definition and description of the primary and secondary outcomes assessment can be found in our previous paper \[[@CR14]\]. For ethical reasons, each patient will act as its own control. The study was approved by the Ethics Committees of our hospital center (reference number 84/2012) and NOVA Medical School/ Faculdade de Ciências Médicas da Universidade Nova de Lisboa (number 36/2014/CEFCM). Written informed consent was obtained from all patients.

Sleep study and CPAP titration {#Sec4}
------------------------------

The diagnosis of OSA was confirmed by home respiratory poligraphy (Embletta® system, Broomfield, USA), which includes continuous recording from nasal cannulae (pressure and flow), thoracic-abdominal motion, pulse oximetry, electrocardiogram and body position sensor. Respiratory events were classified using standard criteria \[[@CR15]\].

All patients performed CPAP titration using an automatic auto-CPAP device (ResMed S9 AutoSet, California, USA) for 3 nights, and subsequent change to CPAP \[[@CR16]\]. After downloading the data from CPAP's card, the definite value of CPAP was the amount of pressure that eliminates events in 95% of sleep time.

Carotid-femoral pulse wave velocity (cf-PWV) study {#Sec5}
--------------------------------------------------

Assessment of cf-PWV was made using a non-invasive automatic device (Complior®, Colson, Paris). Measurements were performed in the morning, without prior consumption of tea or coffee. The assessment was performed in the supine position, and the values ​​took into account the concomitant arterial BP \[[@CR5]\].

CF-PWV was measured using the «foot-to-foot» velocity method from the pressure waveforms, obtained using surface tonometry probes at the right common carotid artery and the right femoral artery. The time delay (Dt, or transit time) is measured between the «foot» of these two waveforms. The distance D covered by the waves is incorporated to the skin distance the two tonometry probes, i.e. the common carotid artery and the common femoral artery. PWV is estimated as PWV = D/Dt (m/s) \[[@CR5]\].

Statistical analysis {#Sec6}
--------------------

Patients' characteristics were described using the mean and standard deviation (SD) for continuous variables, and frequencies (percentages) for categorical variables. To compare characteristics of patients before and after CPAP therapy, Wilcoxon signed rank test and McNemar test were used. In this analysis, demographic variables, sleep study parameters, blood tests and vascular parameters were used. Additionally, in order to investigate associations between these variables and cf-PWV, linear mixed effects regression models were applied. All the variables that attained a *p*-value ≤0.25 were considered for the multivariable analysis. As in this analysis an interaction was identified between ESS group and time (defined by the two assessment instants: before and after CPAP), a stratified analysis by ESS group was also performed in order to investigate potential associations between baseline variables and changes in cf-PWV (∆cf-PWV = cf-PWV before CPAP- cf-PWV after CPAP). In this stratified analysis, linear regression models were only used in the non-sleepy group, attending to the small sample size of sleepy patients' group.

The level of significance α = 0.05 was considered. All data were analyzed using the Statistical Package for the Social Sciences for Windows 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp.) and Stata (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.).

Results {#Sec7}
=======

Forty-two patients with moderate to severe OSA were recruited for this study.

Three patients refused the treatment and five patients dropped out later due to poor compliance to CPAP treatment.

The final cohort included 34 patients, 13 (38.2%) patients with daytime sleepiness, 19 (55.9%) patients with moderate OSA and 15 with severe OSA. Clinical characteristics of patients and home respiratory poligraphy data are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical characteristics of patients before and after CPAP therapy (*n* = 34)VariablesBefore CPAPAfter CPAP*p*-valueAge55.2 (7.9)----BMI31.2 (4.1)31.3 (4.0)0.901Smoking7 (20.6)----ESS \>108.4 (4.3)4.8 (2.7)\<0.001^\*^AHI (events/h)35.2 (18.8)2.6 (2.3)\<0.001ODI (events/h)25.5 (20.0)----Mean SaO~2~ (%)92.1 (2.1)----Lower SaO~2~ (%)79.8 (8.5)----SaO~2~ \< 90% (%)17.7 (18.5)----Total cholesterol, mg/dl198.2 (32.9)187.4 (36.0)0.021HDL-cholesterol, mg/dl44.3 (10.3)44.5 (11.0)0.678LDL-cholesterol, mg/dl131.0 (29.4)121.5 (30.8)0.031Triglycerides, mg/dl137.9 (51.0)126.6 (59.6)0.124Glucose, mg/dl98.7 (12.8)98.2 (11.7)0.924HbA1c, %5.7 (0.4)5.8 (0.4)0.06424 h SBP (mm Hg)129.8 (10.5)128.0 (10.3)0.28724 h DBP (mm Hg)82.4 (7.1)79.2 (6.4)0.004Pulse pressure (mm Hg)47.4 (7.3)48.8 (8.1)0.05024 h MBP (mm Hg)97.4 (7.9)94.9 (7.2)0.030Day-time SBP (mm Hg)133.3 (10.5)131.2 (10.9)0.214Day-time DBP (mm Hg)85.4 (7.3)81.6 (6.9)0.001Night-time SBP (mm Hg)117.9 (12.6)116.4 (9.5)0.363Night-time DBP (mm Hg)72.1 (9.1)70.1 (5.9)0.169Hypertension n (%)27 (79.4)25 (73.5)0.500^\*^Antihypertensive drugs, n (%)21 (61.8)----Dyslipidaemia n (%)28 (82.4)24 (70.6)0.125^\*^Lipid lowering drugs n (%)14 (41.2)----MetS n (%)21 (61.8)20 (58.8)1.000^\*^Cf-PWV (m/s)12.3 (2.3)11.7 (1.8)0.086Results are expressed as mean (standard deviation); \**p*-values obtained by McNemar test; remaining *p*-values were obtained by Wilcoxon rank exact test*CPAP* continuous positive airway treatment, *BMI* Body mass index, *ESS* Epworth Sleepiness Scale, *AHI* Apnea/Hypopnea Index, *ODI* Oxygen Desaturation Index, *SaO* ~*2*~ arterial oxygen saturation, *HbA1c* glycated haemoglobin, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *MetS* metabolic syndrome, cf*-PWV* carotid-femoral pulse wave velocity

Most patients (27; 79.4%) were hypertensive; 6/27 (22.2%) had no treatment and 21/27 (77.8%) were under antihypertensive medication. In 14/27 (51.9%) patients BP was uncontrolled; 10/21 (47.6%) patients were on monotherapy, 7/21 (33.3%) and 4/21 (19.0%) patients were on two or three antihypertensive drugs, respectively. Dyslipidaemia was highly prevalent, as well as metabolic syndrome (MetS) \[[@CR17]\].

Effects of CPAP {#Sec8}
---------------

After four months of CPAP, there was a significant decrease of ESS (*p* ≤ 0.001). Regarding AHI, there was also a significant decrease (*p* \< 0.001) (Table [1](#Tab1){ref-type="table"}), with a mean compliance to CPAP treatment of 5.7 (1.1) hours, and a mean pressure of CPAP 9.3 (0.2).

There was an improvement in some metabolic parameters, namely total cholesterol (*p* = 0.021) and LDL-cholesterol (*p* = 0.031). After treatment with CPAP there was a non-significant decrease in dyslipidaemia prevalence (*p* = 0.125) (Table [1](#Tab1){ref-type="table"}).

There was also an improvement in BP parameters, with a decrease in 24 h diastolic BP (DBP) (*p* = 0.004), daytime DBP (*p* = 0.001) and 24 h mean BP (MBP) (*p* =  0.030), and with an increase in pulse pressure (*p* = 0.050). Non-dipping prevalence in 24 h BP evaluation decreased from 7 (20.6%) to 5 (14.7%) patients, without significance (*p* = 0.500).

Also, a weak evidence of a decrease of cf-PWV values was found (*p* = 0.086) (Table [1](#Tab1){ref-type="table"}). Although without statistical significance, the prevalence of normal cf-PWV (\<10 m/s) increased from 5/34 (14.7%) to 9/34 (26.5%) patients (*p* = 0.289).

Parameters related to cf-PWV {#Sec9}
----------------------------

In univariable analysis there was an association between age, ESS, 24 h SBP, daytime SBP, night-time SBP, pulse pressure, the use of antihypertensive drugs and the presence of MetS with higher values of cf-PWV (Table [2](#Tab2){ref-type="table"}).Table 2Univariable regression analysis for cf-PWVVariablesCoefficient estimate (95% CI)*p*-valueTime−0.52 (−1.06; 0.02)0.057Age0.11 (0.04; 0.02)0.002BMI0.01 (−0.14; 0.17)0.899Smoking−0.47 (−2.05; 1.11)0.561ESS0.13 (0.04; 0.23)0.004ESS \>10−0.15 (−1.47; 1.17)0.822AHI (events/h)0.01 (−0.03; 0.04)0.725ODI (events/h)0.01 (−0.03; 0.04)0.705Mean SaO~2~ (%)−0.06 (−0.37; 0.26)0.730Lower SaO~2~ (%)0.04 (−0.04; 0.11)0.366SaO~2~ \< 90% (%)−0.002 (−0.04; 0.03)0.917CPAP compliance−0.09 (−0.67; 0.48)0.752Total cholesterol, mg/dl−0.002 (−0.02; 0.02)0.794HDL-cholesterol, mg/dl−0.05 (−0.10; 0.01)0.127LDL-cholesterol, mg/dl−0.01 (−0.03; 0.01)0.554Triglycerides, mg/dl0.01 (−0.00; 0.02)0.168Glucose, mg/dl0.02 (−0.01; 0.05)0.229HbA1c, %0.41 (−0.076; 1.59)0.49024 h SBP (mm Hg)0.09 (0.04; 0.14)\<0.00124 h DBP (mm Hg)0.05 (−0.01; 0.12)0.109Pulse pressure (mm Hg)0.15 (0.08; 0.21)\<0.00124 h MBP (mm Hg)0.04 (−0.02; 0.10)0.224Day-time SBP (mm Hg)0.09 (0.04; 0.13)\<0.001Day-time DBP (mm Hg)0.04 (0.02; 0.11)0.167Night-time SBP (mm Hg)0.07 (0.03; 0.11)0.002Night-time DBP (mm Hg)0.05 (−0.01; 0.11)0.109Hypertension1.29 (−0.24; 2.81)0.099Antihypertensive drugs1.37 (0.13; 2.61)0.030Dyslipidaemia0.49 (−1.19; 2.17)0.569Lipid lowering drugs0.22 (−1.09; 1.52)0.745MetS1.44 (0.18; 2.70)0.025*CPAP* continuous positive airway treatment, *BMI* Body mass index, *ESS* Epworth Sleepiness Scale, *AHI* Apnea/Hypopnea Index, *ODI* Oxygen Desaturation Index, *SaO* ~*2*~ arterial oxygen saturation, *HbA1c* glycated haemoglobin, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *MetS* metabolic syndrome, cf*-PWV* carotid-femoral pulse wave velocity, p-values were obtained by linear mixed effects regression models

Relating to the group of patients with MetS and comparing to the patients without MetS, there was a higher prevalence of hypertension (*p* = 0.004) and antihipertensive drugs (*p* \< 0.001). Triglycerides (*p* = 0.002) and glucose (*p* = 0.003) levels were higher, but presented lower HDL-cholesterol levels (*p* = 0.004) and lower mean SaO~2~ (*p* = 0.002).

Moreover, levels of cf-PWV were higher than in patients without MetS, both at baseline (*p* = 0.04) and follow up (*p* = 0.04).

Results of the multivariable regression model showed an association between ESS group and cf-PWV after adjusting by age, pulse pressure and time.

The final multivariable linear mixed regression model (Table [3](#Tab3){ref-type="table"}), after taking into account the coefficient estimate of the interaction term, revealed a different effect of CPAP in the two groups of patients, with a more significant reduction from baseline in cf-PWV in sleepy (1.31 m/s) than in non-sleepy (0.24 m/s) patients. Regarding ESS group, still considering the coefficient estimate of the interaction term, a higher cf-PWV difference between the two groups exists at baseline (1.23 m/s) when compared to four months later values (0.15 m/s) (Fig. [1](#Fig1){ref-type="fig"}).Table 3Multivariable regression analysis for cf-PWVVariablesCoefficient estimate (95%CI)*p*-valueAge0.07 (0.01; 0.13)0.015Time−0.24 (−0.89; 0.41)0.470Pulse pressure (mm Hg)0.16 (0.10; 0.21)\<0.001ESS \>101.23 (0.18; 2.27)0.022Time×ESS\*−1.07 (−2.05; −0.09)0.033*ESS* Epworth Sleepiness Scale; \*interaction term of ESS group and time (defined by the two assessment instants: before and after CPAP); *p*-values were obtained by linear mixed effects regression models Fig. 1Interaction between ESS group and time regarding cf-PWV measurements. Time: 1-before CPAP; 2- after CPAP. Sleepy group: ESS \> 10; non-sleepy group: ESS ≤ 10. ESS- Epworth Sleepiness Scale

Moreover, for each increase of 1 year of age there was a cf-PWV mean increase of 0.07 m/s, and for each mm Hg increase in pulse pressure there was a cf-PWV mean increase of 0.16 m/s.

Stratified analysis by sleepy and non-sleepy patients {#Sec10}
-----------------------------------------------------

At baseline, sleepy patients had higher AHI than their counterparts, with 44.8 (19) events/h vs 29.7 (15.7) events/h (*p* = 0.018). No differences were found in age, BMI, or metabolic parameters between these two groups. There was also no difference in the prevalence rates of BP, antihipertensives or lipid lowering drugs (Table [4](#Tab4){ref-type="table"}).Table 4Demographic and clinical characteristics of patients before and after CPAP therapy by ESS groupSleepy (*n* = 13)Non-sleepy (*n* = 21)VariablesBefore CPAPAfter CPAPBefore CPAPAfter CPAPAge55.08 (6.2)--55.19 (9.0)--BMI31.5 (3.6)31.1 (3.4)31.1 (4.4)31.3 (4.5)Smoking, n (%)2 (15.3%)--5 (23.8%)--ESS^\#^13 (1.8)^\*^5.9 (3.3)^\*^5.5 (2.4)^\*^4.1 (2.0)^\*^AHI (events/h)^\#^44.8 (19.0)^\*^4.0 (3.0)^\*^29.7 (15.7)^\*^1.9 (1,2)^\*^ODI (events/h)^\#^35.8 (21.4)--19.2 (16.6)--Mean SaO~2~ (%)91.2 (2.4)--92.6 (1.7)--Lower SaO~2~ (%)^\#^71 (7.6)--77.1 (8.3)--SaO~2~ \< 90% (%)^\#^26.9 (22.8)--12.1 (12.7)--Total chol, mg/dl199.4 (34.0)188.4 (42.5)200.5 (34.3)186.5 (30.5)HDL-cholesterol, mg/dl44.7 (12.0)44.8 (12.1)44.0 (9.1)44.3 (10,3)LDL-cholesterol, mg/dl128.3 (31.6)122.5 (33.1)135.4 (28.6)^\*^120.6 (30.0)^\*^Triglycerides, mg/dl117.7 (37.7)120.1 (64.4)154.3 (56.0)132.1 (56.9)Glucose, mg/dl101.4 (11.8)97.2 (13.9)96.8 (13.1)98.9 (10.2)HbA1c, %5.7 (0.4)5.9 (0.4)5.7 (0.4)5.8 (0.3)24 h SBP (mm Hg)128.8 (9.8)125.0 (9.2)130.6 (11.2)130.3 (10.8)24 h DBP (mm Hg)83.7 (7.7)^\*^78.7 (5.9)^\*^81.5 (6.7)79.6 (6.9)Pulse pressure (mm Hg)45.2 (4.6)46.3 (6.9)49.1 (8.6)50.7 (8.7)24 h MBP (mm Hg)97.9 (8.5)^\*^92.8 (6.4)^\*^97.1 (7.6)96.4 (7.5)Dt SBP (mm Hg)133.3 (9.4)127.6 (9.5)134.8 (11.6)133.9 (11.3)Dt DBP (mm Hg)86.5 (7.8)^\*^80.9 (6.4)^\*^84.5 (7.1)^\*^82.1 (7.4)^\*^Nt SBP (mm Hg)117.8 (11.9)116.7 (9.5)118.0 (13.4)116.1 (9.8)Nt DBP (mm Hg)74.1 (9.2)71.0 (5.7)70.7 (9.1)69.4 (6.2)Hypertension, n (%)11 (84.6%)--16 (76.2%)--Hypertensive drugs, n (%)8 (61.5%)--13 (61.9%)--Dyslipidemia, n (%)11(84.6%)--17 (81.0%)--Lipid lowering drugs, n (%)5 (38.5%)--9 (42.9%)--MetS n (%)8 (61.5%)--14 (66.7%)--cf-PWV (m/s)12.5 (1.9)^\*§^11.3 (1.6)^\*^12.1 (2.6)^£^12.04 (2.0)Results are expressed as mean (standard deviation); *ESS* Epworth Sleepiness Scale, *AHI* apnea/hypopnea index, *ODI* oxygen desaturation index, *SaO* ~*2*~ arterial oxygen saturation, *SaO* ~*2*~ *\< 90%* time under 90%, *HDL* high density lipoprotein, *LDL* low density lipoprotein, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *Dt* day-time, *Nt* night-time, *MetS* metabolic syndrome, cf*-PWV* carotid-femoral pulse wave velocity; ^\#^ *p* \< 0.05 comparison between sleepy and non-sleepy groups, at baseline (Mann-Whitney test); ^\*^ *p* \< 0.05 comparison between before and after CPAP, in each ESS group (Wilcoxon signed rank test), for cf-PWV (m/s): §*p* = 0.012; £*p* = 0.779, in sleepy and non-sleepy group, respectively

After treatment with CPAP, and regarding cf-PWV, there was a significant decrease in sleepy patients (*p* = 0.012) and a non-significant decrease in non-sleepy patients (*p* = 0.779).

In non-sleepy patients, the change in cf-PWV after four months of CPAP was associated most strongly with pulse pressure (coefficient estimate = 0.08 m/s; 95% CI, 0.01 to 0.15, *p* = 0.034) (Additional file [1](#MOESM1){ref-type="media"}).

Also, there was a weak association between cf-PWV change with triglycerides (coefficient estimate = 0.01 m/s; 95% CI, −0.00 to 0.03, *p* = 0.080), and with the presence of lipid lowering drugs (coefficient estimate = 1,23 m/s; 95% CI, −0.09 to 2.56, *p* = 0.066).

To identify the associated variables with cf-PWV changes between baseline and after four months of CPAP therapy, multiple linear regression analysis was performed, revealing that higher pulse pressure was associated with higher cf-PWV changes and higher LDL-cholesterol levels were associated with lower cf-PWV changes (Table [5](#Tab5){ref-type="table"}).Table 5Results of multivariable model corresponding to cf-PWV changes among 21 patients without daytime sleepinessVariablesCoefficient estimate (95%CI)*p*-valuePulse pressure (mm Hg)0.13 (0.07; 0.19)0.001LDL-cholesterol (mm Hg)−0.03 (−0.05; −0.01)0.015*LDL* low density lipoprotein. Overall model adjusted R^2^ = 0.71

Discussion {#Sec11}
==========

This study is the first to attempt to identify characteristics of sleepy and non-sleepy patients that might justify the different effects of CPAP on arterial stiffness.

Selecting a cohort of male patients with moderate to severe OSA and without a great number of comorbidities, we found a high prevalence of hypertension, dyslipidaemia and MetS.

After four months of CPAP treatment there was an improvement in 24 h DBP, daytime DBP, and levels of total cholesterol. Age and SBP were variables associated to cf-PWV, as expected, but daytime sleepiness was also detected. In multivariable analysis, we found that sleepy and non-sleepy groups behaved differently, under CPAP treatment. In the fitted model, sleepiness was an independent determinant of the longitudinal decrease in cf-PWV (*p* = 0.033 for interaction with time), after adjusting for covariates, meaning time, age and pulse pressure.

Analysing the subgroup of non-sleepy patients, a high pulse pressure and lower levels of LDL cholesterol were predictive of higher cf-PWV changes, in a model where 71% of cf-PWV variability was explained by those independent variables.

The strengths of our study settled, thus, in the use of a standardized marker of vascular disease and stiffness (cf-PWV), and the evaluation of CPAP compliant patients.

There are at least two meta-analysis \[[@CR6], [@CR7]\] identifying a decrease in arterial stiffness after CPAP treatment in patients with OSA, and in patients with OSA and hypertension; only four from the selected studies evaluated the effect on cf-PWV.

The effect of CPAP reducing cf-PWV was well described in studies with highly selected samples, including very severe and younger OSA patients \[[@CR18], [@CR19]\], or less obese patients \[[@CR20]\] than those that we recruited, and this is due to the absence of comorbidities, namely hypertension. Also, in those studies patients were mainly symptomatic and sleepy.

Kohler et al. \[[@CR21]\] studied 208 patients less symptomatic, with ESS 8.4 (4), and found that, after six months of CPAP, arterial stiffness (measured by AIx) did not improve, compared to controls. However, patients included in that study had a milder OSA than ours and the median compliance of CPAP was 2.8 h per night. Moreover, in the subgroup with higher compliance there were not significant changes in arterial stiffness, either.

In contrast with these results, in a meta-regression analysis examining the effect of potential modifiers upon the effect of CPAP on arterial stiffness, the sleepiness score did not have significance \[[@CR6]\].

We admit that the role of sleepiness as well as the usefulness of cf-PWV measurements may be best defined in this sample under 60 years old and without a great number of comorbidities, yet very prevalent in the clinical set.

Concerning the improvement in lipid profile, our results are in agreement with the meta-analysis results of Nadeem et al. CPAP treatment seems to improve dyslipidaemia, although we did not find an increase in HDL-cholesterol as described \[[@CR22]\].

MetS was associated to higher levels of cf-PWV, but it was not included in the multivariable regression model. Patients with MetS were found to have significantly higher baseline and follow up levels of cf-PWV than patients without MetS, besides a more severe OSA defined by lower mean SaO~2~ levels. In fact, MetS is an additive factor to arterial wall damage and only in very selected populations it has been possible to demonstrate a reduction of some of the syndrome components or its prevalence \[[@CR23]\].

We found, among the variables selected, that pulse pressure was positively related to cf-PWV values, as well as SBP parameters. In the non-sleepy group analysis pulse pressure was predictive of greater cf-PWV changes, and other BP variables were excluded from the model.

The predominant association of pulse pressure with cf-PWV variations is interesting as it is probably related to early vascular ageing of OSA patients. Pulse pressure has showed the strongest association with aortic cf-PWV over other haemodynamic BP parameters, namely from age 60 years and over, where it begins to increase precipitously. In OSA patients, Sanner et al. also found that a higher pulse pressure before treatment with CPAP was predictive of a beneficial CPAP effect on BP, over other BP parameters \[[@CR24]\].

In the sleepy group of patients and after adjusting for age and pulse pressure, there was a reduction of cf-PWV of 1.31 m/s from baseline. Also, and though there was no difference between groups, we found a difference among them of 0.15 m/s, after CPAP therapy.

This is relevant as an increase in aortic PWV by 1 m/s is known to correspond to an age-, sex-, and risk factor-adjusted risk increase of 14%, 15%, and 15% in total CV events, CV mortality, and all-cause mortality, respectively \[[@CR25]\].

Patients with daytime sleepiness tend to experience more severe OSA \[[@CR26]\], and the severity of OSA could influence the results of CPAP therapy. In this study, the group of sleepy patients has higher AHI, ODI and SaO~2~ \< 90% than the non-sleepy patients. However, sleep study parameters were not correlated to cf-PWV changes, neither predictive of a better outcome in non-sleepy group of patients.

The issue of sleepiness as an independent variable was raised in studies on OSA and hypertension \[[@CR27]\]. CPAP significantly reduces BP in patients with OSA but with a low effect size \[[@CR28]\]. When non-sleepy/less symptomatic patients were evaluated, a DBP reduction of less than 1 mmHg was found in compliant patients and may be significant, but its clinical meaning is debatable \[[@CR11]\]. Daytime sleepiness was also identified as independent variable predicting BP changes in patients with OSA under CPAP \[[@CR29]\].

In our study, non-sleepy patients had a mean compliance of 5.9 (0.22) hours, and a significant reduction of 2.4 mmHg occurred in daytime DBP.

Regarding the mechanisms involved in the pathophysiology of daytime sleepiness, some studies suggest that it is related to sleep fragmentation \[[@CR30]\], while others have found an association with both nocturnal hypoxemia \[[@CR31]\] and changes produced by intermittent hypoxemia.

One possible explanation for our findings is based in the knowledge that daytime sleepiness is related to both the systemic inflammation associated with sleep disruption (sleep fragmentation and arousals) and to the severity of nocturnal desaturation, which appears to be the primary proatherogenic feature of OSA \[[@CR32]\]. It may thus represent the global effect of OSA severity factors.

Study limitations {#Sec12}
-----------------

Limitations of this study were the small sample size, though it was not an obstacle for the general aim, and the lack of a control group, which makes this study mainly hypothesis generating. The results cannot be extended to women, the elderly or patients with comorbidities. The use of polysomnography instead of home respiratory poligraphy would allow a more complete evaluation of associations between sleep variables and cf-PWV changes, although it was time consuming and uncomfortable for patients with active working life.

Conclusions {#Sec13}
===========

In a cohort of consecutive middle aged men with moderate to severe OSA, mainly with metabolic syndrome and dyslipidaemia, it was found a significant decrease in cf-PWV, in sleepy but not in non-sleepy patients. In non-sleepy patients, pulse pressure and LDL-cholesterol at baseline were predictive of higher cf-PWV changes. Further studies are needed to confirm the use of cf-PWV as a biomarker of response to CPAP therapy in OSA patients with sleepiness and good compliance to the treatment.

Additional file {#Sec14}
===============

Additional file 1: Table S1.Univariable regression analysis investigating associations between variables and ∆cf-PWV, in non-sleepy patients. (DOCX 13 kb)

AHI

:   Apnea-hypopnea index

BP

:   blood pressure

Cf-PWV

:   carotid-femoral pulse wave velocity

CPAP

:   continuous positive airways pressure

CV

:   cardiovascular

DBP

:   diastolic blood pressure

ESS

:   Epworth Sleepiness Scale

HDL

:   high-density lipoprotein

LDL

:   low density lipoprotein

OSA

:   obstructive sleep apnea

SBP

:   systolic blood pressure
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